Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States
Work
Year: 2021
Type: article
Abstract: To estimate the cost-effectiveness of sequential use of the sodium-glucose co-transporter-2 inhibitor empagliflozin and glucagon-like peptide-1 receptor agonist liraglutide after metformin in patients... more
Source: Diabetes Obesity and Metabolism
Authors Odette S. Reifsnider, Pratik Pimple, Sarah Brand, Evelien Bergrath Washington, Sharash Shetty +1 more
Cites: 30
Cited by: 11
Related to: 10
FWCI: 1.767
Citation percentile (by year/subfield): 86.88
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder Boehringer Ingelheim